Notice on publicly soliciting the opinions of the "Principles of the Principles of Clinical R & D Technical Guidance for the Treatment of Ovarian Cancer (Draft for Soliciting Opinions)"

At this stage, there is no domestic technical guidance principle of clinical research and development of ovarian cancer in China. The existing guidance principles cannot cover the considerations of clinical trial design specifically for ovarian cancer. In order to further clarify the technical principles, improve the efficiency of new drug research and development, the clinical clinical drugsA relevant indication group organized the "Principles of the Principles of the New Research and Development Technology of New Drugs for the treatment of ovarian cancer", forming a draft for soliciting opinions for reference for the relevant personnel of drug research and development.

We sincerely welcomes all sectors of society to put forward valuable opinions and suggestions on the drafts of soliciting opinions, and timely feedback to us in time for follow -up improvement.The time limit for soliciting opinions is 1 month from the date of release.

For your feedback, please send it to the mailbox of the contact person below:

Contact: Zhang Hong, Hu Wenjuan

Contact: [email protected], [email protected]

Thank you for your participation and strong support.

Drug Review Center

September 26, 2022

Scan code View attachment:

Source: Drug Review Center of the State Drug Administration

- END -